Farnesyltransferase inhibitors (FTI) have been developed as anticancer drugs and are currently being evaluated in clinical trials. In this study, we have examined the effects of FTIs on Tsc-null cells to gain insight into their effects on farnesylated Rheb GTPase. This protein is involved in the activation of mTOR/S6K signaling and is down-regulated by the Tsc1/Tsc2 complex. Both Tsc1 À/À and Tsc2 À/À mouse embryonic fibroblasts exhibit constitutive activation of S6K and grow in the absence of serum. Two different FTI compounds, the clinical compound BMS-214662 and the newly described BMS-225975, inhibit the constitutive activation of mTOR/S6K signaling and block serum-free growth of the Tsc-null mouse embryonic fibroblasts. We have also found that Tsc-null mouse embryonic fibroblasts grow under anchorage-independent conditions and that both FTI compounds inhibit this soft agar growth. These FTI effects are similar to those observed with rapamycin. Another interesting phenotype of Tsc-null mouse embryonic fibroblasts is that they are round and contain actin filaments predominantly at the cell periphery. The addition of FTIs, but not rapamycin, led to the reappearance of intracellular actin filaments and reduction of peripheral actin filaments. The ability of FTI to rearrange actin filaments seems to be largely mediated by the inhibition of Rheb protein, as induction of intracellular actin filaments by FTI was much less efficient in Tsc2-null cells expressing Rheb (M184L), a geranylgeranylated mutant Rheb that can bypass farnesylation. These results reveal that FTIs inhibit Rheb, causing two different effects in Tsc-deficient cells, one on growth and the other on actin filament distribution. [Mol Cancer Ther 2005;4(6):918 -26] 
Introduction
Farnesyltransferase inhibitors (FTI) have been developed as anticancer drugs and are currently being evaluated in phase II and phase III clinical trials (1 -4) . Clinical activities have been observed with hematopoietic malignancies and breast cancer (1 -4) . One of the recent advances in the development of FTIs is the generation of a novel, highly specific FTI compound BMS-225975 (5) . This compound is a derivative of a clinical compound BMS-214662 (6, 7), a tetrahydrobenzodiazepine FTI identified through a screen for a thiol surrogate which could function as a zinc ligand. Replacing the hydrogen on the imidazole of BMS-214662 with a methyl group on the tau nitrogen generated BMS-225975 (5) . BMS-225975 exhibits slightly increased potency for farnesylation inhibition. At the same time, BMS-225975 is devoid of the apoptosis induction activity observed with BMS-214662 on some cancer cell lines. With the use of both these compounds, cellular effects due to the inhibition of farnesylation can be more clearly defined.
Although FTIs were initially developed as an inhibitor of Ras proteins, recent studies suggest that there are other target proteins. No correlations between FTI sensitivity and ras mutation status have been established (8, 9) . Furthermore, K-Ras4B has been shown to be resistant to FTIs, as this protein undergoes geranylgeranylation when farnesylation is inhibited (10, 11) . Proposed FTI targets include RhoB, CENP-E,F and Rheb (1, 12) . Among these proteins, Rheb is of particular interest. We, as well as others, have recently established that Rheb activates S6K and this activation is inhibited by rapamycin, suggesting that the signaling is mediated through mTOR (13 -16) . Expression of dominant-negative Rheb mutants blocked nutrient-or serum-induced activation of S6K (17) . Rheb also plays important roles in tuberous sclerosis, an autosomal dominant genetic disorder that afflicts 1 in 6,000 to 10,000 individuals (18) . The disorder is associated with the appearance of benign tumors called hamartomas at different parts of the body including brain, kidney, lung, and skin (18) . Neurologic symptoms include mental retardation, seizure, and autism. A lung disease called lymphagioleiomyomatosis is also associated with tuberous sclerosis in women (19) . Mutations in TSC1 or TSC2 genes are responsible for tuberous sclerosis (18) . The TSC1 and TSC2 gene products form a complex that functions as a GTPase activating protein for Rheb (13 -16) .
Rheb protein is farnesylated, and our studies in yeast have established that this posttranslational modification is required for the function of Rheb (20) . Clark et al. (21) showed that farnesylation facilitates membrane association of mammalian Rheb. Tee et al. (22) reported that a farnesylation defective mutant of Rheb is less efficient in activating S6K, and Castro et al. (23) and Uhlmann et al. (24) showed that FTI inhibits Rheb activation of S6K. On the other hand, Li et al. (25) recently reported that farnesylation is not essential for the function of Rheb to activate S6K. Thus, the significance of farnesylation for the function of mammalian Rheb needs to be further investigated. To gain insight into the effect of FTI on Rheb, we focused on Tsc-deficient cells derived from Tsc knock-out mice. Homozygous Tsc knock-out mice die during embryogenesis due to defects in liver development, whereas heterozygous Tsc1 or Tsc2 knock-out mice commonly develop tumors including renal cystadenomas and liver hemangiomas (26, 27) . Activation of Rheb has been detected in Tsc2 À/À mouse embryonic fibroblasts (28) . These mouse embryonic fibroblast cells exhibit constitutive activation of S6K and altered growth properties that include serum-independent growth and loss of contact inhibition (29 -31) .
In this paper, we show that both FTI compounds inhibit altered growth and signaling properties of Tsc À/À mouse embryonic fibroblasts. We also show that Tsc-null mouse embryonic fibroblasts are able to grow in anchorageindependent conditions that can be inhibited by FTIs. We found that the Tsc2 À/À mouse embryonic fibroblasts exhibit altered morphology, and actin filaments are predominantly localized in the periphery of cells. FTIs were capable of reversing this phenotype leading to the appearance of intracellular actin filaments and reduction of peripheral actin filaments. Interestingly, rapamycin was incapable of affecting the actin cytoskeleton. By using a mutant Rheb that can bypass farnesylation, we obtained evidence that the effect of FTI on the actin cytoskeleton is mediated by its effect on Rheb. The significance of these observations on the dual role of Rheb on growth and morphology is discussed. À/À mouse embryonic fibroblasts are immortalized by the introduction of p53 deficiency (26, 31) .
Materials and Methods

Cell Lines and Cell Culture
Tsc2 À/À p53 À/À , Tsc2 +/+ p53 À/À ,
Construction of Plasmids
Hemagglutinin-tagged wild-type and mutant Rheb (Rheb1) were subcloned into pCDNA3myc to generate myc-hemagglutinin-tagged Rheb. pCDNA3myc was generated by cloning a linker containing a single myc epitope with the Kozak sequence into the HindIII/NheI restriction sites of pCDNA3HA to replace the hemagglutinin epitopes with a myc epitope. pCDNA3HA was generated by cloning triple hemagglutinin tags followed by an NheI restriction site into the HindIII/EcoRI restriction sites of pCDNA3 (Invitrogen, San Diego, CA). Rheb (C181S) farnesylation-defective mutant and Rheb (M184L) geranylgeranylated mutant were generated by two-step PCR mutagenesis using pCMV5-hemagglutinin-Rheb (WT) as a template (17) . Both strands were sequenced to confirm the correct sequence. Mutant hemagglutinin-tagged Rheb cDNAs were subcloned into pCDNA3-myc to generate pCDNA3-mycHARheb (C181S) and pCDNA3-mycHARheb (M184L). pCMV5-Flag-p70
S6K was described previously (17) .
Cell Viability and Cell Cycle Analysis Cells (5 Â 10 3 ) were plated in 96-well plates. For serum starvation experiments, Tsc2 À/À and control mouse embryonic fibroblasts were serum-starved in DMEM supplemented with nonessential amino acids (Life Technologies) for 1 to 3 days. Tsc1 À/À and control mouse embryonic fibroblasts were starved in DMEM supplemented with 0.1% (v/v) fetal bovine serum, and nonessential amino acids for 1 to 3 days. For drug treatment, Tsc À/À and control mouse embryonic fibroblasts were treated with the appropriate drug in either serum-starved medium (as indicated above) or normal medium for 1 to 3 days. For each time point, 20 AL 2.5 mg/mL 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT; Sigma, St. Louis, MO) was added to cells in 100 AL of medium and incubated for 2 to 3 hours at 37jC. Cells were lysed in 100 AL of MTT lysis buffer [20% (w/v) SDS, 0.5% (v/v) 80% (v/v) acetic acid, 0.4% (v/v) 1 N HCl, 50% (v/v) N,Ndimethylformamide] and the absorbance at 570 nm was determined using a Revelation plate reader. The background absorbance at 630 nm was subtracted. Relative cell viability was calculated as a fold-increase from the reading at day 0. Cell cycle profile was analyzed as described previously (32) with the following modifications. Cells (2 -3 Â 10 5 ) were plated in 60 mm plates. Rapamycin was obtained from Calbiochem (La Jolla, CA). BMS-225975 and BMS-2214662 were kindly provided by Dr. Veeraswamy Manne (Bristol-Myers Squibb). Other chemicals were obtained from Sigma.
Anchorage-Independent Growth
Soft agar assays were done as described (32) with the following modifications. Mouse embryonic fibroblasts were seeded at densities of 3 Â 10 3 to 10 4 cells per well in a 24-well plate. Images of colonies in soft agar were analyzed at 100Â magnification.
Immunoblot Analysis For serum starvation experiments, 24 hours after seeding, cells were incubated for 24 hours in DMEM supplemented with nonessential amino acids. For drug treatments, cells were treated with the appropriate drug for 48 hours in either serum-free or normal growing medium. Total cell lysates were prepared as described previously (17) . Antiphospho p70 S6K (T389) antibody, anti-phospho S6 (S235/ 236) antibody, and anti-S6 antibody were obtained from Cell Signaling (Beverly, CA). Anti-p70 S6K antibody was obtained from Santa Cruz (Santa Cruz, CA) and anti-HDJ2 antibody was obtained from NeoMarkers (Fremont, CA) and anti-myc 9B11 was obtained from Cell Signaling.
Immunofluorescence Tsc2 À/À mouse embryonic fibroblasts were treated with various inhibitors as indicated. Cells were stained with antimyc 9E10 (BAbCO, Richmond, CA) and FITC anti-mouse IgG (Sigma) antibodies or TRITC-phalloidin (Sigma) as described previously (32) . Images were analyzed using a Nikon Eclipse TE300 Diaphot microscope with Epifluorescence attachment and a CCD camera system (Photometrics, CoolSNAPfx) supported by the MetaMorph software.
Results
Altered Signaling and Growth Properties of Tsc
À/À
Mouse Embryonic Fibroblasts
Tsc À/À mouse embryonic fibroblasts exhibit a striking change in signaling and growth properties compared with control Tsc +/+ mouse embryonic fibroblasts. One of the major alterations concerns constitutive activation of mTOR/S6K signaling. The Tsc1/Tsc2 complex functions as a GTPase activating protein for Rheb (13 -16) , and activation of Rheb is reported in the Tsc2 À/À mouse embryonic fibroblasts as detected by the increased ratio of GTP/GDP bound to Rheb (28) . Figure 1A shows constitutive activation of S6K in Tsc À/À mouse embryonic fibroblasts as detected by the use of an antibody specific to phospho-S6K (T389). With the control Tsc1 +/+ mouse embryonic fibroblasts, phosphorylation of S6K was decreased upon serum starvation and induced at a high level only after the addition of serum (Fig. 1A, left) . In contrast, phosphorylation of S6K was constitutively upregulated in Tsc1 À/À mouse embryonic fibroblasts even in the absence of serum. Similar constitutive activation of S6K was observed in Tsc2 À/À mouse embryonic fibroblasts (Fig.  1A, right) . In addition, S6, a downstream substrate of S6K, was also constitutively activated in Tsc À/À mouse embryonic fibroblasts (data not shown). Our results agree with those of previous studies (26, 29, 31) .
In addition, Tsc À/À mouse embryonic fibroblasts grow in the absence of serum. Tsc2
À/À cells continue to grow after serum withdrawal, whereas Tsc2 +/+ mouse embryonic fibroblasts stop growing (Fig. 1B, right) . Similar serumindependency was observed with Tsc1 À/À mouse embryonic fibroblasts (Fig. 1B, left) . Serum-independent growth was more pronounced with Tsc2 À/À mouse embryonic fibroblasts, which may reflect the lack of p53 in this cell line (31) . The serum-independent growth of Tsc2 À/À mouse embryonic fibroblasts was further investigated by examining their cell cycle profiles. As shown in Fig. 1C , the cell cycle profile of Tsc2 À/À mouse embryonic fibroblasts was not affected upon serum withdrawal, whereas it led to a significant accumulation of G 0 /G 1 phase cells in Tsc2
À/À mouse embryonic fibroblasts with rapamycin resulted in increase of G 0 /G 1 phase cells, suggesting that the serum-independent growth phenotype is mediated through the mTOR pathway and that the cell cycle machinery involved in G 1 -S transition is intact. Similar results were obtained when we examined the cell cycle profiles of these cells at high confluency. Tsc2 À/À mouse embryonic fibroblasts failed to arrest at G 0 /G 1 phase, whereas significant accumulation of G 0 /G 1 phase cells was observed with Tsc2 +/+ mouse embryonic fibroblasts (Fig. 1D) . Although Tsc2 À/À mouse embryonic fibroblasts showed higher saturation densities than Tsc2 +/+ mouse embryonic fibroblasts, they did not form foci when we did a focus formation assay (data not shown).
FTIs Inhibit Altered mTOR/S6K Signaling and Growth Properties of Tsc-Null Mouse Embryonic Fibroblasts
To examine the effects of FTIs on the altered signaling and growth properties of Tsc -null mouse embryonic fibroblasts, we used two different FTI compounds, BMS-214662 and BMS-225975. These compounds inhibit the protein farnesyltransferase reaction in vitro with IC 50 value of f1 nmol/L. In vivo, BMS-214662 and BMS-225975 induce reversion of H-ras transformed Rat1 cells with IC 50 values of 0.1 and 0.02 Amol/L, respectively (5). Figure 2A shows that BMS-214662 and BMS-225975 inhibit farnesylation of ectopically expressed Rheb and cause a mobility shift to a slower migrating unmodified form with concentrations as little as 0.25 Amol/L in human embryonic kidney-293 cells. BMS-225975 was slightly more potent than BMS-214662, in agreement with its increased ability to inhibit farnesylation. The farnesylation defective mutant of Rheb, Rheb (C181S), was expressed as a control unmodified form. Figure 2B shows the effect of FTIs on S6K activation induced by the expression of Rheb. Under starved conditions, overexpressed S6K is not phosphorylated in COS-7 cells. However, coexpression with Rheb significantly induced phosphorylation of S6K. This Rheb-induced activation of S6K was inhibited by the treatment of cells with 1 Amol/L BMS-225975. In addition, Rheb (C181S), did not activate S6K (Fig. 2B) .
Both FTI compounds were capable of inhibiting the constitutive activation of S6K and S6 in Tsc À/À mouse embryonic fibroblasts. Tsc À/À mouse embryonic fibroblasts were treated with BMS-225975 or rapamycin in serum-free medium. Figure 2C shows that phosphorylation of S6K in the Tsc1 À/À mouse embryonic fibroblasts was inhibited by the incubation with BMS-225975 in a dose-dependent manner.
Constitutive activation of S6 was also inhibited by the treatment with BMS-225975 in the Tsc2 À/À mouse embryonic fibroblasts. The inhibition of farnesylation was assessed by the shift in mobility of HDJ-2, a farnesylated chaperone protein commonly used as a marker for the inhibition of farnesylation (33) .
The effects of FTIs on the serum-independent growth of Tsc À/À mouse embryonic fibroblasts were examined (Fig. 2D) . Both BMS-225975 and BMS-214662 were able to inhibit the serum-free growth of Tsc2 À/À mouse embryonic fibroblasts. After incubation for 2 to 3 days, FTIs' effects were similar to those observed with rapamycin. The effects of FTIs required prolonged incubation, whereas the rapamycin effect was more immediate, presumably reflecting the fact that FTIs inhibit farnesylation of newly synthesized proteins and cannot inhibit the function of preexisting farnesylated proteins. With Tsc1 À/À mouse embryonic fibroblast, BMS-225975 showed significant inhibition, whereas the effects of BMS-214662 were weak.
Tsc
À/À Mouse Embryonic Fibroblasts Exhibit Anchorage-Independent Growth and This Phenotype Is Inhibited by FTI Another striking feature of Tsc-null cells is their ability to grow under anchorage-independent conditions. We examined growth of Tsc À/À mouse embryonic fibroblasts derived from Tsc knock-out mice in soft agar and found that the Tsc À/À mouse embryonic fibroblasts can grow in soft agar when seeded at high densities. As can be seen in Fig. 3A , both Tsc1 À/À and Tsc2 À/À mouse embryonic fibroblasts form multicellular colonies in soft agar particularly when plated at high densities, whereas this growth was not observed with the control wild-type mouse embryonic fibroblasts. Anchorage-independent growth was more pronounced with Tsc2 À/À mouse embryonic fibroblasts, which may be due to the lack of p53 in this cell line (31) . The ability of Tsc2 À/À mouse embryonic fibroblasts to grow in an anchorage-independent manner is also supported by our observation that they grow on a plate Figure 1 . A, Tsc -null mouse embryonic fibroblasts have a higher level of S6K phosphorylation than control mouse embryonic fibroblasts in serum-starved conditions. Cells were starved for 24 h (À). Cells were starved and then stimulated for 15 min with 20% fetal bovine serum (+). Phosphorylated and total levels of S6K were examined as described in Materials and Methods. Results are representative of three independent experiments. B, growth of
Tsc1
À/À and control mouse embryonic fibroblasts in serum-free medium (left ); growth of Tsc2 À/À and control mouse embryonic fibroblasts in serum-free medium (right ). Twenty-four hours after seeding, cells were changed to medium without serum. Cell viability was assayed using an MTT assay. Points, means; bars, SD. C, Tsc2 À/À mouse embryonic fibroblasts do not arrest in G 0 /G 1 during serum starvation. Tsc2 mouse embryonic fibroblasts were collected at 60% confluency, whereas they were exponentially growing in normal medium or after serum starvation for 24 h. Cell cycle profile was then analyzed as described in Materials and Methods. Results are representative of three independent experiments. D, cell cycle profile of Tsc2 À/À mouse embryonic fibroblasts were analyzed in exponentially growing conditions (48 h, 60% confluency) or in contact inhibited conditions (72 h, 100% confluent). Results are representative of three independent experiments. coated with polyHEMA (data not shown). The anchorageindependent growth of Tsc-null mouse embryonic fibroblasts we observed, however, was not as vigorous as those of other human cancer -derived cell lines or ras-transformed fibroblasts. This agrees with the observation that a special condition (a higher concentration of agar compared with conventional conditions used for human cancer derived cell lines) is needed, in this case, to detect anchorage-independent growth of Tsc2 À/À fibroblasts derived from Eker rat (34) . Figure 3B shows the effect of FTIs on the anchorageindependent growth of Tsc-null mouse embryonic fibroblasts. Treatment of Tsc1 À/À mouse embryonic fibroblasts as well as Tsc2 À/À mouse embryonic fibroblasts with BMS-214662 or BMS-225975 effectively inhibited the formation of colonies in soft agar. Inhibition of anchorageindependent growth was also observed with rapamycin and LY294002.
Tsc2-Null Mouse Embryonic Fibroblasts Exhibit Altered Morphology and Actin Filament Distribution in a FTI-Sensitive and Rapamycin-Insensitive Manner
The above results show that FTIs are capable of inhibiting serum-free as well as anchorage-independent growth of Tsc-null cells and that these effects seem to be due to their effects on the inhibition of S6K. These effects are similar to those elicited by rapamycin, an inhibitor of the mTOR/raptor complex. We have observed additional effects of FTIs that seem to be independent of the mTOR/raptor complex inhibition. Viewed under a phase-contrast microscope, Tsc2 À/À mouse embryonic fibroblasts exhibit altered morphology compared with the control mouse embryonic fibroblasts.
Tsc2
À/À mouse embryonic fibroblasts seem rounded, whereas the control mouse embryonic fibroblasts are stretched out with the typical fibroblastic extensions. Phalloidin staining revealed differences in the distribution of actin filaments in the Tsc2 À/À and the control mouse embryonic fibroblasts. Although actin filaments are dispersed intracellularly in the control Tsc2 +/+ mouse embryonic fibroblasts (Fig. 4, top left) , actin filaments are assembled mainly at the cell periphery, reminiscent of lamellipodia, in Tsc2 À/À mouse embryonic fibroblasts (Fig. 4, top right) .
Effects of FTI on the morphology of these mouse embryonic fibroblasts have been examined. With Tsc2 +/+ mouse embryonic fibroblasts, no major changes in actin filaments were observed upon treatment with FTIs (Fig. 4,  left) . In contrast, treatment of the Tsc2 À/À mouse embryonic fibroblasts with FTIs resulted in the reduction of peripheral actin and redistribution of intracellular actin filaments (Fig. 4, right) . These intracellular actin filaments are well aligned, similar to what is seen in the Tsc2 mouse embryonic fibroblasts. A more potent FTI compound BMS-225975 induced changes in cell morphology. In contrast to the results with FTIs, treatment with rapamycin did not affect the distribution of actin cytoskeleton in the Tsc2 À/À and Tsc2 +/+ mouse embryonic fibroblasts (Fig. 4, bottom) .
Effect of FTIs on Actin Cytoskeleton Is Mediated by the Inhibition of Rheb
The above effect of FTIs on actin cytoskeleton is of particular interest, as this is not observed with rapamycin. To examine whether this FTI effect is mediated by the inhibition of Rheb, we expressed a mutant form of Rheb that can bypass the farnesylation requirement. This was accomplished by mutating the COOH-terminal methionine to leucine, thus converting the CaaX motif to the CaaL motif (1, 35) . The CaaL motif is recognized by geranylgeranyltransferase type I, and the resulting mutant protein can be modified by geranylgeranylation instead of farnesylation. Thus, expression of the mutant Rheb, Rheb (M184L), is expected to generate cells that are resistant to FTI. Tsc2-null mouse embryonic fibroblasts were transiently transfected with the myc-tagged Rheb (M184L) and effects on actin filaments in the cells expressing Rheb (M184L) were examined by costaining with anti-myc antibody and phalloidin (Fig. 5) . First, we confirmed that expression of Rheb (M184L) itself did not alter actin distribution in Tsc2 À/À mouse embryonic fibroblasts (see Fig. 5 , DMSO). Expression of Rheb (M184L) also did not cause any evident change in the peripheral actin in Tsc2 +/+ mouse embryonic fibroblasts (data not shown). We next examined if there is a differential response to FTIs with or without expression of mutant Rheb in Tsc2 À/À mouse embryonic fibroblasts. As shown in Fig. 5 , the cells expressing Rheb (M184L) were resistant to the effect of FTIs as both BMS-214662 or BMS-225975 failed to induce intracellular actin and the peripheral accumulation of actin remained unchanged. In contrast, the actin cytoskeleton in cells not expressing Rheb (M184L) was significantly affected by FTI treatment. These results suggest that expression of the mutant Rheb confers resistance to FTIs in Tsc2 À/À mouse embryonic fibroblasts. 
Discussion
FTIs are capable of inhibiting Rheb farnesylation. FTIs inhibit constitutive activation of S6K and S6 in Tsc-null mouse embryonic fibroblasts. Serum-independent growth as well as anchorage-independent growth of these cells is inhibited by FTIs. To confirm that the effects of FTIs reflect their inhibition of farnesylation, we used two different FTI compounds. Both compounds elicited similar effects. In addition, we have observed a correlation between the concentrations of FTIs needed to inhibit the altered growth phenotypes of Tsc-null mouse embryonic fibroblasts and those needed to inhibit farnesylation of Rheb as well as HDJ-2 proteins. These results, taken together, strongly suggest that FTIs are capable of inhibiting Rheb's function to activate mTOR/S6K. The observation that rapamycin causes effects similar to those seen with FTI further supports this idea.
Our results showing that FTIs have the ability to inhibit altered growth and signaling properties of Tsc À/À mouse embryonic fibroblasts with potency comparable to that observed with rapamycin raises the possibility that FTIs provide an effective reagent to treat benign tumors in tuberous sclerosis. It will be interesting to examine whether FTIs can elicit tumor response similar to that observed with rapamycin in Tsc-deficient mice or in the Eker rat. Rapamycin has been shown to reduce proliferation of tumor cells and prolong survival of Eker rats that carry a germ line Tsc2 mutation (36, 37) . Decreased serum vascular endothelial growth factor levels and apoptosis in tumors were detected in Tsc1 +/À mice treated with rapamycin (38) . The availability of multiple drugs that can influence Tscdeficient phenotypes represents an important advance towards developing effective therapy against tuberous sclerosis. Another implication of our work is that FTIs may be effective in inhibiting transformed phenotypes of human cancer cells with Rheb activation. In prostate cancer, Akt is frequently activated due to the loss of Pten, thus, leading to the activation of the Akt/mTOR/S6K signaling (39) . Her2 overexpression is seen in a significant percentage of breast cancer (40) , which results in the activation of Akt (41) . It will be important to examine whether Rheb is activated in human cancer cell lines that have the activation of the phosphoinositide-3-kinase/ mTOR signaling pathway, and to investigate the effect of FTIs on theses cell lines. Our study with FTI uncovered another role of Rheb in Tsc-null cells. First, we noticed that Tsc2 À/À mouse embryonic fibroblast cells appear as rounded cells, whereas the control Tsc2 +/+ mouse embryonic fibroblast cells are stretched out. In the Tsc2 À/À mouse embryonic fibroblasts, actin filaments were predominantly assembled around the cell periphery giving an appearance resembling lamellipodia and membrane ruffles. In addition, these cells have increased adherence compared with the control cells. 1 The peripheral actin distribution in Tsc2 À/À mouse embryonic fibroblasts we observed is different from the distribution of actin filaments in the Eker ratderived smooth muscle cells recently reported by Goncharova et al. (42) . This apparent difference is presumably due to the difference in cell lines used. We further showed that the treatment with FTIs leads to the rearrangement of actin filaments specifically in Tsc2 À/À mouse embryonic fibroblasts but not in control mouse embryonic fibroblasts. This FTI effect is mediated by the inhibition of Rheb, as shown by the use of a Rheb mutant that can bypass farnesylation: overexpression of a geranylgeranylated Rheb mutant conferred Tsc2 À/À mouse embryonic fibroblasts resistance to the FTI. Thus, Rheb is involved in rearrangement of actin cytoskeleton in Tsc2 À/À mouse embryonic fibroblasts. It has been reported that Tsc1 interacts with the ERM proteins and activates Rho (43) and regulates the assembly of intracellular actin filaments (42, 43) . Activation of Rho by Tsc2 has also been reported (44) . Further work is needed to clarify the contribution of Tsc1/2 and Rheb to the regulation of the actin cytoskeleton.
It is interesting that rapamycin was incapable of affecting the actin cytoskeleton. These results suggest that there are two distinct pathways downstream of Rheb, one signaling to growth and the other affecting the actin cytoskeleton. The pathway affecting growth is rapamycin-sensitive and is likely to involve a rapamycin-sensitive mTOR complex that contains raptor and signals to S6K (45) . On the other hand, the pathway affecting actin cytoskeleton is rapamycin-insensitive. What pathway could be responsible for the effect? We initially considered the possibility that FTI suppresses the inhibitory action of Rheb on B-Raf (46, 47) , resulting in the activation of the MEK/ROCKII/LIMK/ cofilin signaling pathway (48) . However, this seems unlikely because MEK inhibitors, PD98059 and U0126, showed no effects on actin filaments in Tsc2 mouse embryonic fibroblasts.
1 A more likely possibility involves a recently identified second mTOR complex, mTORC2. The mTORC2 contains a novel protein Rictor/mAVO3 and mediates signals to actin cytoskeleton in a rapamycininsensitive manner (49, 50) . Inactivation of mTORC2 components causes decreased Rac activity, which in turn leads to rearrangement of the actin cytoskeleton: decrease in the cortical actin, cell spreading, and adhesion and increase in cytoplasmic actin filaments (49, 50) . Our findings of lamellipodia-like peripheral actin distribution and increase in adhesion in Tsc2 À/À mouse embryonic fibroblasts suggest that mTORC2 plays an important role in the phenotypes of Tsc2 À/À mouse embryonic fibroblasts. With our observation that FTI affects both growth and actin cytoskeleton in Tsc2 À/À mouse embryonic fibroblasts through the inhibition of Rheb, it is tempting to speculate that Rheb transmits signals not only to the mTOR/raptor complex but also to the mTORC2. Further experiments using FTIs may provide important insight into how Rheb influences growth and actin cytoskeleton.
